Table of ContentsIntroductionRead (pg. 5)Fast Track Designations: Trends & Strategic InsightsRead (pg. 6)Breakthrough Therapy Designations: Trends & Strategic InsightsRead (pg. 7)Accelerated Approvals: Trends & Strategic InsightsRead (pg. 8)Priority Review: Trends & Strategic InsightsRead (pg. 9)Orphan Drug Designations: Trends & Strategic InsightsRead (pg. 10)Accelerating Access and Innovation in HealthcareRead (pg. 11)Expedited Drug Journeys in 2026Read (pg. 12)Top Therapeutic Areas in Expedited PathwaysRead (pg. 13)Benefits, Risks and Stakeholder ImpactRead (pg. 14)Strategic Implications for IndustryRead (pg. 15)Future Outlook for Expedited Pathway in 2026Read (pg. 16)Expedited Pathways & Biopharma DealmakingRead (pg. 17)ConclusionRead (pg. 18)ReferencesRead (pg. 21)Pharma Insight Reportshttps://adisinsight.springer.com/insight-hub